Telix Pharmaceuticals (NASDAQ:TLX) Hits New 52-Week Low - Should You Sell?

Key Points

• Telix Pharmaceuticals (NASDAQ:TLX) reached a new 52-week low with its stock price dropping to $10.50 before recovering slightly to $10.90, having traded with a volume of 12,869 shares.
• Analysts remain optimistic, with multiple firms issuing buy ratings and price targets ranging from $22.00 to $23.00, suggesting a consensus target price of $22.33.
• Several hedge funds have altered their positions in Telix Pharmaceuticals recently, indicating growing investment interest, with notable acquisitions totaling over $4 million in new stakes.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $10.50 and last traded at $10.90, with a volume of 12869 shares. The stock had previously closed at $11.30.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on TLX shares. Wedbush restated an "outperform" rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Thursday, June 12th. HC Wainwright started coverage on shares of Telix Pharmaceuticals in a report on Thursday, July 3rd. They set a "buy" rating and a $23.00 price target for the company. Finally, William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Telix Pharmaceuticals has an average rating of "Buy" and an average target price of $22.33.

Telix Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66. The company's fifty day moving average is $14.47 and its two-hundred day moving average is $16.27.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Private Advisor Group LLC acquired a new position in shares of Telix Pharmaceuticals during the first quarter worth $170,000. ABC Arbitrage SA acquired a new position in shares of Telix Pharmaceuticals during the first quarter worth $451,000. Blair William & Co. IL acquired a new position in shares of Telix Pharmaceuticals during the second quarter worth $217,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Telix Pharmaceuticals during the second quarter worth $297,000. Finally, Pier Capital LLC acquired a new position in shares of Telix Pharmaceuticals during the second quarter worth $3,037,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.